Skip to content

About Us

Page 'Sub' Navigation:

Page Path 'Breadcrumb':

Board of Directors

Felix J. Baker, PhD
Managing Partner
Baker Bros. Advisors, LLC

Dr. Baker was appointed as one of our directors in February 2010. Dr. Baker currently serves as a managing partner of Baker Bros. Advisors, LLC, the manager and advisor to the funds of Baker Brothers Investments, Ardea’s largest shareholder. Baker Brothers Investments, founded by Felix and Julian Baker in 2000, is a family of long-term investment funds for major endowments and foundations, which are focused on publicly traded life sciences companies. Felix Baker began his career as a fund manager by co- founding a biotechnology investment partnership in 1994. Felix Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school.


Wendy L. Dixon, PhD

Dr. Dixon was appointed as one of our directors in April 2011. From December 2001 to May 2009, Dr. Dixon was Chief Marketing Officer and President, Global Marketing for Bristol-Myers Squibb, a biopharmaceutical company and served on the CEO’s Executive Committee. From 1996 to 2001, she was Senior Vice President, Marketing at Merck and prior to that she held executive management positions at West Pharmaceuticals, Osteotech, Inc. and Centocor, Inc. and various positions at SmithKline & French Pharmaceuticals (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon serves on the boards of directors of Furiex Pharmaceuticals, Inc., Orexigen Therapeutics, Inc., Incyte Corporation and Alkermes, Inc., and was previously a director of DENTSPLY International from 2005 to 2010. Dr. Dixon received her MSc and BSc in Natural Science and her Ph.D. in Biochemistry from the University of Cambridge. Dr. Dixon’s 33-year career in the pharmaceutical and biotechnology business, combining a technical background and experience in drug development and regulatory affairs with commercial responsibilities in building and leading organizations and launching and growing more than 20 pharmaceutical products including Tagamet®, Fosamax®, Singulair®, Plavix®, Abilify®, Reyataz® and Baraclude®, brings to the Board a wealth of broad-ranging and hands-on experience in drug development.


Henry J. Fuchs, MD
Senior Vice President and Chief Medical Officer
BioMarin Pharmaceutical Inc.

Dr. Fuchs has served as one of our directors since November 2001. Dr. Fuchs currently serves as Senior Vice President and Chief Medical Officer of BioMarin Pharmaceutical Inc. Previously he served as Executive Vice President and Chief Medical Officer of Onyx Pharmaceuticals. He served as our Chief Executive Officer from January 2003 until June 2005. Dr. Fuchs joined us as Vice President, Clinical Affairs in October 1996 and was appointed President and Chief Operating Officer in November 2001. From 1987 to 1996, Dr. Fuchs held various positions at Genentech where, among other responsibilities, he led the clinical program that resulted in the approval of Genentech’s Pulmozyme®. Dr. Fuchs was also responsible for the Phase III development program that led to the approval of Herceptin® to treat metastatic breast cancer. Dr. Fuchs received an MD degree from George Washington University and a BA degree in biochemical sciences from Harvard University.


Craig Johnson
Chief Financial Officer
PURE Bioscience, Inc.

Mr. Johnson has served as one of our directors since June 2008. Mr. Johnson currently serves as Chief Financial Officer of PURE Bioscience, Inc. Prior to PURE Bioscience, he served as Senior Vice President and Chief Financial Officer of NoveDel Pharma Inc. from 2010 to 2011. From 2004 to 2010, Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. From 1994 to 2004, he was employed by MitoKor, Inc. and last held the position of Chief Financial Officer and Senior Vice President of Operations. Prior to joining MitoKor, Mr. Johnson served as a senior financial executive for several early-stage technology companies, and he also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson received his B.B.A. in accounting from the University of Michigan and is a certified public accountant.


John Poyhonen, MBA
President, Chief Operating Officer
Senomyx, Inc.

Mr. Poyhonen was appointed as a director in June 2007. Mr. Poyhonen is currently the President and Chief Operating Officer of Senomyx, Inc. He joined Senomyx in October 2003 as Vice President and Chief Business Officer and was promoted in April 2004 to Vice President and Chief Financial and Business Officer. He was promoted to his current position in September 2009. From 1996 until October 2003, Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, a Pfizer, Inc. company, most recently as Vice President of National Sales. Prior to holding this position, Mr. Poyhonen served as Vice President of Marketing and Vice President of National Accounts. Mr. Poyhonen received his B.A. in Marketing from Michigan State University and his M.B.A. from the University of Kansas.


Barry D. Quart, PharmD
President, Chief Executive Officer and Director
Ardea Biosciences, Inc.

Dr. Quart was elected as a director and appointed as our President and CEO in December, 2006. From 2002 until December, 2006, Dr. Quart was President of Napo Pharmaceuticals, Inc., where he was instrumental in bringing the company public on the London Stock Exchange in July 2006. Prior to Napo, Dr. Quart was Senior Vice President, Pfizer Global Research and Development and the Director of Pfizer's La Jolla Laboratories, where he was responsible for approximately 1,000 employees and an annual budget of almost $300 million. Prior to Pfizer's acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, since 1999. Dr. Quart had joined Agouron in 1993 and was instrumental in the development and registration of nelfinavir (Viracept®), which went from the lab bench to NDA approval in 38 months. Dr. Quart spent over ten years at Bristol-Myers Squibb in both Clinical Research and Regulatory Affairs prior to Agouron and was actively involved in the development and registration of important drugs for the treatment of HIV and cancer, including paclitaxel (Taxol®), didanosine (Videx®), and stavudine (Zerit®). He has a PharmD from University of California, San Francisco.


Kevin C. Tang
Managing Director
Tang Capital Management, LLC

Mr. Tang has served as one of our directors since May 2003. Mr. Tang is the Managing Director of Tang Capital Management, LLC, a life sciences-focused investment company he founded in August 2002. From September 1993 to July 2001, Mr. Tang held various positions at Deutsche Banc Alex. Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm's life sciences research group. Mr. Tang currently serves as a director of A.P. Pharma, Inc. Mr. Tang received a BS degree from Duke University.